NASDAQ:SANA Sana Biotechnology (SANA) Stock Price, News & Analysis $6.40 +0.35 (+5.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.15▼$6.6150-Day Range$5.08▼$8.6352-Week Range$2.74▼$12.00Volume1.36 million shsAverage Volume2.55 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$12.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Sana Biotechnology alerts: Email Address Sana Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside99.2% Upside$12.75 Price TargetShort InterestBearish23.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.15) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.15 out of 5 starsMedical Sector606th out of 936 stocksBiological Products, Except Diagnostic Industry96th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingSana Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSana Biotechnology has only been the subject of 2 research reports in the past 90 days.Read more about Sana Biotechnology's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.13% of the float of Sana Biotechnology has been sold short.Short Interest Ratio / Days to CoverSana Biotechnology has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Sana Biotechnology has recently increased by 7.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSana Biotechnology does not currently pay a dividend.Dividend GrowthSana Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SANA. Previous Next 3.2 News and Social Media Coverage News SentimentSana Biotechnology has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sana Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for SANA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders31.10% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.23% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sana Biotechnology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sana Biotechnology are expected to grow in the coming year, from ($1.15) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sana Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sana Biotechnology is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSana Biotechnology has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sana Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About Sana Biotechnology Stock (NASDAQ:SANA)Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Read More SANA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SANA Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comStock Traders Purchase Large Volume of Sana Biotechnology Put Options (NASDAQ:SANA)July 14, 2024 | seekingalpha.comSana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T PipelineJuly 26, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.May 21, 2024 | finance.yahoo.comSana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative ConditionsMay 16, 2024 | msn.comStanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia StakeMay 10, 2024 | finance.yahoo.comSana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial ResultsMay 9, 2024 | markets.businessinsider.comSana Biotechnology: Promising Clinical Studies and Breakthrough Potential in T1D TherapyMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sana Biotechnology Amidst Strong Clinical Progress and Solid FinancialsJuly 26, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.May 8, 2024 | investorplace.comSANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024May 8, 2024 | sfgate.comSana: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comSana Biotechnology Reports First Quarter 2024 Financial Results and Business UpdatesMay 6, 2024 | globenewswire.comSana Biotechnology to Present at May and June 2024 Investor ConferencesMay 2, 2024 | finance.yahoo.comNvelop Therapeutics Announces Members of Its Scientific Advisory BoardMay 1, 2024 | finance.yahoo.comSana Biotechnology, Inc. (SANA) Stock Price, News, Quote & History - Yahoo FinanceApril 26, 2024 | msn.comTech Moves: Seattle tech vet Dave Parker named CEO of Entrepreneurs’ OrganizationApril 22, 2024 | bizjournals.comSana Biotechnology R&D leader Douglas Williams steps downApril 20, 2024 | investing.comSana Biotechnology EVP Williams resigns from R&D postSee More Headlines Receive SANA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SANA CUSIPN/A CIK1770121 Websana.com Phone206-701-7914FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$12.75 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+99.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-283,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-88.13% Return on Assets-47.16% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book4.38Miscellaneous Outstanding Shares221,503,000Free Float152,616,000Market Cap$1.42 billion OptionableOptionable Beta1.45 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Steven D. Harr M.D. (Age 54)President, CEO & Director Comp: $1.04MMs. Robin Andrulevich (Age 58)Executive VP & Chief People Officer Dr. Edward Rebar Ph.D. (Age 56)Head of Cell Engineering Mr. Paul Brunetta M.D.Senior VP and Head of Clinical & Translational ScienceMr. Christian Hordo M.B.A. (Age 41)Executive VP & Chief Business Officer Comp: $485.03kDr. Sonja Schrepfer M.D. (Age 49)Ph.D., Senior VP & Head of Hypoimmune Platform Dr. Terry Fry M.D. (Age 57)Senior VP & Head of T Cell Therapeutics Dr. Steven A. Goldman M.D. (Age 66)Ph.D., Senior VP & Head of CNS Therapy Ms. Farah AnwarHead of Development Operations & IDE LeaderDr. Gary Meininger M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsXencorNASDAQ:XNCRVeracyteNASDAQ:VCYTHarmony BiosciencesNASDAQ:HRMYSage TherapeuticsNASDAQ:SAGEFulgent GeneticsNASDAQ:FLGTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 90,423 shares on 7/26/2024Ownership: 0.195%Baillie Gifford & Co.Sold 85,079 shares on 7/25/2024Ownership: 4.773%Clarius Group LLCBought 16,359 shares on 7/11/2024Ownership: 0.029%Teachers Retirement System of The State of KentuckySold 17,000 shares on 5/28/2024Ownership: 0.047%Zimmer Partners LPBought 202,500 shares on 5/17/2024Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions SANA Stock Analysis - Frequently Asked Questions How have SANA shares performed this year? Sana Biotechnology's stock was trading at $4.08 at the start of the year. Since then, SANA shares have increased by 56.9% and is now trading at $6.40. View the best growth stocks for 2024 here. How were Sana Biotechnology's earnings last quarter? Sana Biotechnology, Inc. (NASDAQ:SANA) announced its earnings results on Wednesday, May, 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02. When did Sana Biotechnology IPO? Sana Biotechnology (SANA) raised $322 million in an initial public offering on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO. Who are Sana Biotechnology's major shareholders? Sana Biotechnology's top institutional investors include Baillie Gifford & Co. (4.77%), Bank of New York Mellon Corp (0.19%) and Clarius Group LLC (0.03%). Insiders that own company stock include Robert Nelsen, Ventures Fund V Gener Flagship, Christian Hordo, Joshua H Bilenker and James J Macdonald. View institutional ownership trends. How do I buy shares of Sana Biotechnology? Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SANA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sana Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sana Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.